2. Kok E.T., Schouten B.W., Bohnen A.M., Groeneveld F.P., Thomas S.,Bosch J.L. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen study. J Urol. 2009;181:710–716.

3. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A.,et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol. 1997;158:481–487.

4. Bosch J.L., Hop W.C., Kirkels W.J., Schrцder F.H. Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. Urology. 1995;46:34–40.

5. Fong Y.K., Milani S., Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. CurrOpin Urol. 2005;15:35–38.

6. Guess H.A., Arrighi H.M., Metter E.J., Fozard J.L. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241–246.

7. Chaitoff A., Killeen T.C., Nielsen C. Men’s health 2018: BPH, prostate cancer, erectile dysfunction, supplements. Cleve Clin J Med. 2018;85(11):871–880. Doi: 10.3949/ccjm.85a.18011.

8. Rosen. RC., Giuliano F., Carson C.C. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(6):824–837.

9. Roehrborn C.G., Nuckolls J.G. at al. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.BJU Int. 2007;100(4):813–819.

10. Shiri R., Häkkinen J.T. at al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction.J Urol. 2005l;174(1):205–209.

11. Mondul A.M., Rimm E.B. et al. A prospective study of lower urinary tract symptoms and erectile dysfunction.J Urol. 2008;179(6):2321–2326.

12. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5

13. Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol. 2014;6(4):135–147. Doi:10.1177/1756287214531639

14. Kedia G., Uckert S. at all Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology 73: 1397–1401.

15. Filippi, S., Morelli, A., at al. Characterization and functional role of androgen- dependent PDE5 activity in the bladder. Endocrinology. 2007;148:1019–1029.

16. Yoshimura N., Seki S. De Groat W. Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol. 2001;86:304–311.

17. Morelli A., Sarchielli E. et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746–2760.

18. Bertolotto M., Trincia et al. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med. 2009;114:1106–1114.

19. Roumeguere T., Zouaou iBoudjeltia К. et al. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 2010;57: 522–528.

20. Choi H., Kim H.J., Bae J.H., et al. A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction. IntNeurourol J. 2015;19(4):237–245.

21. Laydner H.K., Oliveira Р. et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU International. 2011;107:1104–1109.

22. Wang Y., Bao Y. et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis. Lower Urinary Tract Symptoms. 2018;10:84–92.

23. Oelke M., Giuliano F. at al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. Eur Urol. 2012;6(5):917–925.